Elixir Medical Corp
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Elixir Medical Corp
The 2018 EuroPCR meeting in Paris featured new results from clinical trials of coronary stents from Biotronik, Amaranth, Medtronic, MicroPort, and Hexacath.
The EuroPCR conference in Paris is the most important annual interventional cardiology conference in Europe and this year's edition brought more data from clinical trials of both established catheter-based technologies and innovative new devices.
A letter to Abbott's customers states that the company will restrict its Absorb bioresorbable stent to registries in Europe while it investigates possible safety issues flagged in clinical trials.
Preliminary two-year results from the randomized AIDA trial comparing Abbott's Absorb GT1 BVS and Abbott's Xience Prime drug-eluting stent found patients treated with Absorb were almost four times as likely to develop a stent thrombosis. The results are the latest in disappointing clinical news for the bioabsorbable scaffold.
- Drug Delivery
- Site Specific
Surgical Equipment & Devices
- Minimally or Less Invasive